STABILITY – what went wrong for GSK's darapladib?
This article was originally published in Scrip
The full results from GlaxoSmithKline's failed Phase III STABILITY study of its Lp-PLA2 inhibitor darapladib presented this weekend at the American College of Cardiology meeting in Washington DC shed further light on its clinical profile. While the investigational drug's prospects are not good, the data show that it did at least produce some statistical benefits on some secondary endpoints, leaving some experts with a glimmer of hope that it may prove useful in certain patient subgroups.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.